Avec ses serres sur toits et son réseau de partenaires responsables, les fermes lufa créent un système alimentaire local plus durable, juste et transparent. Visitez notre marché en ligne au www.montreal.lufa.com. By farming on rooftops and partnering with responsible farms and food makers, lufa farms is creating a more sustainable, equitable, and transparent local food system. Visit our online marketplace at www.montreal.lufa.com.
Cellworks group, inc. Is a leader in precision drug development and personalized therapy biosimulation. The cellworks platform predicts therapy response for individual patients and patient cohorts using a breakthrough computational biology model (cbm) and biosimulation technology. Backed by artiman ventures, bering capital, sequoia capital, unitedhealth group and agilent ventures, cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal – attacking serious diseases to improve the lives of patients.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators.
Powered by patented ai and actuarial data, cybersaint's cyberstrong platform enables enterprises to master their cyber risk posture and drive executive alignment by automating compliance and translating cyber risk into financial terms. Fortune 50 titans, msps, and high-growth startups alike trade manual compliance assessments for automation, replace black-box scoring with transparent and credible cyber risk quantification, and consolidate point solutions into a single, intuitive platform.
Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the lumicell direct visualization system, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.